NICE recommends ranibizumab

Article

The National Institute for Health and Clinical Excellence (NICE) recommends the use of ranibizumab for patients with diabetic macular oedema (DME).

The National Institute for Health and Clinical Excellence (NICE) recommends the use of ranibizumab for patients with diabetic macular oedema (DME).

Ranibizumab, the only licensed anti-VEGF treatment for DME, has been issued positive draft guidance from NICE. Patients could soon benefit from the treatment- which could restore vision, prevent visual loss and maintain visual improvement.

Novartis has previously conducted a number of clinical trials on the DME treatment and concluded that the likelihood of gaining 10 or more letters of vision doubled compared to using a laser. With laser therapy three times as many patients could lose vision compared to those who were administered ranibizumab.

The Final Appraisal Document for ranibizumab is expected to be completed by the end of this year and will ensure that as many patients as possible have access to ranibizumab.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
© 2025 MJH Life Sciences

All rights reserved.